FABOMOTIZOLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21N3O2S
Molecular Weight	307.411
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC1=CC2=C(NC(SCCN3CCOCC3)=N2)C=C1

InChI

InChIKey=WWNUCVSRRUDYPP-UHFFFAOYSA-N

InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H21N3O2S
Molecular Weight	307.411
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf
Curator's Comment: description was created based on several sources, including http://pro-pharma.biz/?page_id=171

Fabomotizole (also known as Afobazole) is a selective non-benzodiazepine anxiolytic which was developed in Russia and launched in 2006. The drug is used for the treatment of wide range of diseases: generalized anxious disorders, neurasthenia, adaptation disorders, sleep disorders, for alleviation of withdrawal syndrome. According to the drug label (in Russian), its action is related to the interaction with sigma-1 receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 63 Target ID: CHEMBL287 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Agonist 2678		5.9 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Generalized anxiety disorder 32 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Neurasthenia 5 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Adjustment disorder 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Insomnia 108 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Withdrawal syndrome 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Palliative	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006

PubMed

Title	Date	PubMed
[Pharmacological regulation of emotional stress reactions].	2003	14724970
[Afobazole increases cerebral blood flow in rats with global brain ischemia].	2004 Sep-Oct	15559627
[Aphobazol--new selective anxyolytic drug].	2005	15875941
[Using aphobazol for treatment of the emotional stress after exposure to ionizing radiation].	2005 Apr-Jun	16078648
Neuroprotective properties of afobazol in vitro.	2005 Aug	16282999
[Evidence for the neuroprotective properties of afobazole in experimental model of focal brain ischemia].	2006 Jul-Aug	16995428
[A comparative study of the effect of afobazole on brain monoamine systems in BALB/C and C57BL/6 mice].	2006 Sep-Oct	17153957
[Pharmacokinetics of afobazole in rats].	2007 Mar-Apr	17523455
[Using of aphobazol in the treatment of adaptation disorder in the contract service men, dismissed from the armed forces].	2007 Nov	18306710
Excretion of afobazole and its metabolites with urine and feces in rats.	2008 Apr	19110588
[Afobazole metabolism in rats].	2008 Mar-Apr	18488909
[Neuroprotective effects of afobazole in a hemorrhagic stroke model].	2009 Jan-Feb	19334507
[Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons].	2009 Jan-Feb	19334503
[Afobazole effect on cerebral circulation under hemorrhagic stroke model conditions].	2009 Nov-Dec	20095394
Effect of afobazole on genotoxic effects of tobacco smoke in the placenta and embryonic tissues of rats.	2010 Sep	21246089
[Anxiolytic afobazole action self-evaluated by patients with anxiety-asthenic disorders].	2010 Sep	21086645

Patents

Sample Use Guides

In Vivo Use Guide

For adult persons and children it is recommended to use internally, after meal. Usually it is recommended to use 1 tablet (10 mg) trice per day. The maximum daily dose is 60 mg. The period of therapy is 2-4 weeks. According to doctor prescription it is possible to prolong the period up to 3 months.

Route of Administration: Oral

In Vitro Use Guide

Experiments on immortalized hippocampal cell culture of mice showed that afobazole increases the NGF level in a final concentration of 10(-8) M and the BDNF level in final concentrations from 10(-8) to 10(-5) M.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:50:01 GMT 2023` Edited by `admin` on `Sat Dec 16 17:50:01 GMT 2023`
Record UNII	0F8K1X115C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FABOMOTIZOLE

Official Name

English

AFOBAZOLE

Common Name

English

1H-BENZIMIDAZOLE, 5-ETHOXY-2-((2-(4-MORPHOLINYL)ETHYL)THIO)-

Systematic Name

English

APHOBAZOLE

Common Name

English

AFOBAZOL

Common Name

English

OBENOXAZINE

Common Name

English

Fabomotizole [WHO-DD]

Common Name

English

fabomotizole [INN]

Common Name

English

5-ETHOXY-2-((2-(MORPHOLIN-4-YL)ETHYL)SULFANYL)-1H-BENZIMIDAZOLE

Systematic Name

English

CM-346

Code

English

Classification Tree Code System Code

WHO-ATC

N05BX04